Serum pancreastatin: The next predictive neuroendocrine tumor marker. Issue 2 (15th June 2013)

• Record Type: Journal Article
• Authors: Rustagi, Sapna; Warner, Richard R.P.; Divino, Celia M.
• Is Part Of: Journal of surgical oncology. Volume 108:Issue 2(2013:Aug. 01)
• Page Start: 126
• Page End: 128
• Publication Date: 2013-06-15
• Subjects: Cancer -- Surgery -- Periodicals; Neoplasms -- Periodicals; 616
• DOI: 10.1002/jso.23359
• Languages: English
• ISSNs: 0022-4790

Abstract

<abstract abstract-type="main" xml:lang="en"> <title>Abstract</title> <sec id="jso23359-sec-0001" sec-type="section"> <title>Background and Objectives</title> <p>Pancreastatin is a derived peptide of chromogranin A (CgA). Pancreastatin has the potential to be a diagnostic and predictive tumor marker in detecting NETs.</p> </sec> <sec id="jso23359-sec-0002" sec-type="section"> <title>Methods</title> <p>Radioimmunoassay tests of pancreastatin and CgA were performed on 103 patient specimens collected at Mount Sinai Medical Center between 1/2010 and 7/2012. Patient demographics, diagnostic tests, surgical procedures, pathologic findings, adjuvant treatments, and survival were retrospectively reviewed. Statistical analysis utilized SPSS v20 software.</p> </sec> <sec id="jso23359-sec-0003" sec-type="section"> <title>Results</title> <p>Mean pancreastatin levels were significantly higher in the 92 NETs patients than in the 11 non‐NETs patients (227.261 vs. 59.727, <italic>P</italic> < 0.05). Twenty‐seven of the 92 patients with elevated pancreastatin levels (mean = 240.67), had normal CgA levels (mean = 4.65). Pancreastatin had sensitivity and specificity of 64% (59/92), and 100% (11/11). CgA had lower sensitivity and specificity of 43% (40/92), and 64% (7/11). In all 27 instances the pancreastatin concentration was found to be sole indicator of NET disease. When controlling for the level of CgA for the entire sample, a statistically significant difference was not found in the mean pancreastatin levels between both patient groups (<italic>P</italic> = 0.139, R = 0.484).</p> </sec> <sec id="jso23359-sec-0004" sec-type="section"> <title>Conclusion</title> <p>Pancreastatin has greater sensitivity and specificity in diagnosing NETs than CgA. Further investigation of pancreastatin's diagnostic and predictive value is warranted <italic>J. Surg. Oncol. 2013; 108:126–128</italic>. © 2013 Wiley Periodicals, Inc.</p> </sec> </abstract>